Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Sell
36
HCAT Quote, Financials, Valuation and Earnings
Last price:
$7.08
Seasonality move
:
-12.83%
Day range:
$6.78 - $7.20
52-week range:
$5.42 - $11.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.38x
P/B ratio:
1.21x
Volume:
560.5K
Avg. volume:
555.5K
1-year change:
-26.02%
Market cap:
$430.8M
Revenue:
$295.9M
EPS (TTM):
-$1.35
Analysts' Opinion
-
Consensus RatingHealth Catalyst has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Health Catalyst has an estimated upside of 61.15% from its current price of $7.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.08.
Fair Value
-
According to the consensus of 0 analysts, Health Catalyst has 61.15% upside to fair value with a price target of -- per share.
HCAT vs. S&P 500
-
Over the past 5 trading days, Health Catalyst has overperformed the S&P 500 by 0.9% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Health Catalyst does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Health Catalyst has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Health Catalyst reported revenues of $76.4M.
Earnings Growth
-
Health Catalyst has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Health Catalyst reported earnings per share of -$0.24.
Enterprise value:
388.6M
EV / Invested capital:
0.56x
Price / LTM sales:
1.38x
EV / EBIT:
--
EV / Revenue:
1.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-25.02x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$136.6M
Return On Assets:
-10.95%
Net Income Margin (TTM):
-26.2%
Return On Equity:
-21.76%
Return On Invested Capital:
-12.86%
Operating Margin:
-17.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $271.8M | $290M | $302.1M | $73.8M | $76.4M | |
| Gross Profit | $133M | $132.4M | $136.6M | $32M | $34M | |
| Operating Income | -$148M | -$130.9M | -$85.1M | -$24.6M | -$13.7M | |
| EBITDA | -$98.4M | -$72.5M | -$26.2M | -$10M | $908K | |
| Diluted EPS | -$2.94 | -$2.23 | -$1.35 | -$0.39 | -$0.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $322.8M | $515.3M | $443.5M | $408.5M | $457.4M | |
| Total Assets | $570.7M | $845.5M | $776.2M | $712.9M | $813.1M | |
| Current Liabilities | $65.9M | $263.4M | $91.1M | $84.3M | $323.8M | |
| Total Liabilities | $271M | $296.3M | $336.2M | $330.5M | $458M | |
| Total Equity | $299.6M | $549.2M | $440M | $382.4M | $355M | |
| Total Debt | $166.2M | $177.8M | $226.1M | $227.7M | $345M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$30.2M | -$28.9M | -$955K | $3.1M | $6.2M | |
| Cash From Investing | -$122M | -$3.4M | $119.8M | -$24.9M | $7.6M | |
| Cash From Financing | $666K | $3M | $114.5M | $1M | $112.5M | |
| Free Cash Flow | -$47M | -$44.5M | -$15.5M | $6K | $1.8M | |
HCAT
Sector
Market Cap
$430.8M
$45.9M
Price % of 52-Week High
62.05%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
-4.76%
-0.6%
1-Year Price Total Return
-26.02%
-32.15%
Beta (5-Year)
1.315
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.13
200-day SMA
Sell
Level
$7.24
Bollinger Bands (100)
Sell
Level
7.08 - 8.48
Chaikin Money Flow
Sell
Level
-2.7M
20-day SMA
Sell
Level
$7.81
Relative Strength Index (RSI14)
Sell
Level
37.39
ADX Line
Sell
Level
26.88
Williams %R
Buy
Level
-83.4171
50-day SMA
Sell
Level
$7.99
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
8.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.8389)
Sell
CA Score
(Annual)
Level (-0.7861)
Buy
Beneish M-Score
(Annual)
Level (-2.7838)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (0.9596)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Stock Forecast FAQ
In the current month, HCAT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HCAT average analyst price target in the past 3 months is --.
-
Where Will Health Catalyst Stock Be In 1 Year?
According to analysts, the consensus estimate is that Health Catalyst share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Health Catalyst?
Analysts are divided on their view about Health Catalyst share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Health Catalyst is a Sell and believe this share price will drop from its current level to --.
-
What Is Health Catalyst's Price Target?
The price target for Health Catalyst over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HCAT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Health Catalyst is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HCAT?
You can purchase shares of Health Catalyst via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Health Catalyst shares.
-
What Is The Health Catalyst Share Price Today?
Health Catalyst was last trading at $7.08 per share. This represents the most recent stock quote for Health Catalyst. Yesterday, Health Catalyst closed at $7.08 per share.
-
How To Buy Health Catalyst Stock Online?
In order to purchase Health Catalyst stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
